We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+3.08%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$429M
AUM Growth
-$47.2M
Cap. Flow
-$18.8M
Cap. Flow %
-4.39%
Top 10 Hldgs %
52.29%
Holding
44
New
14
Increased
9
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$32.9M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16.6M
4
RFL icon
Rafael Holdings
RFL
+$13.3M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$12.2M

Top Sells

Rank Stock Value
1
PODD icon
Insulet
PODD
+$28.7M
2
UTHR icon
United Therapeutics
UTHR
+$17.7M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.2M
4
COLL icon
Collegium Pharmaceutical
COLL
+$16M
5
FOLD
Amicus Therapeutics
FOLD
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Real Estate 2.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$681M
$7.19M 1.67%
198,000
+48,000
+32% +$1.89M
SYRE icon
27
Spyre Therapeutics
SYRE
$8.54B
$7.16M 1.67%
36,000
– –
PHAT icon
28
Phathom Pharmaceuticals
PHAT
$708M
$7.09M 1.65%
+220,863
New +$7.34M
APLS
29
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$6.59M 1.53%
+200,000
New +$11.2M
KNSA icon
30
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.47M 1.27%
+480,000
New +$6.25M
PCVX icon
31
Vaxcyte
PCVX
$7.81B
$2.49M 0.58%
+98,061
New +$2.38M
RPTX
32
DELISTED
Repare Therapeutics
RPTX
$2.44M 0.57%
93,137
-342,952
-79% -$11.1M
COLL icon
33
Collegium Pharmaceutical
COLL
$1.15B
$2.4M 0.56%
121,342
-740,068
-86% -$16M
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$2.38M 0.55%
249,000
-1,351,000
-84% -$13.8M
IFRX icon
35
InflaRx
IFRX
$250M
$1.43M 0.33%
551,918
-1,648,082
-75% -$4.34M
PRQR icon
36
ProQR Therapeutics
PRQR
$243M
$254K 0.06%
+30,336
New +$198K
KYNB
37
CALL
Kyntra Bio
KYNB
$27.2M
– –
-20,000
Closed -$13.3M
KURA icon
38
Kura Oncology
KURA
$800M
– –
-500,000
Closed -$10.4M
NTLA icon
39
CALL
Intellia Therapeutics
NTLA
$1.49B
– –
-100,000
Closed -$16.2M
OCUL icon
40
Ocular Therapeutix
OCUL
$1.79B
– –
-919,887
Closed -$13M
PODD icon
41
Insulet
PODD
$11.5B
– –
-104,600
Closed -$28.7M
VERV
42
DELISTED
Verve Therapeutics
VERV
– –
-35,000
Closed -$2.11M
MRTX
43
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$16.2M
XENT
44
DELISTED
Intersect ENT, Inc
XENT
– –
-700,000
Closed -$12M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Great Point Partners held 44 positions worth $429M, down 9.9% from $477M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners withdrew a net $18.8M in Q3 2021, closing 8 positions and reducing 9 holdings. Its most notable exit was Insulet, an estimated $28.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Real Estate.

Against the trend, Great Point Partners opened a new position in BioAtla worth $24.8M.

  • Great Point Partners's largest Q3 2021 buy was BioAtla: 16,880 shares worth $24.8M.
  • Great Point Partners added most to Biogen in Q3 2021, an estimated $4.92M increase.
  • Great Point Partners's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $17.7M.
  • Great Point Partners fully exited Insulet in Q3 2021, selling an estimated $28.7M.
  • Great Point Partners's ten largest holdings make up 52% of its $429M portfolio in Q3 2021.
  • Great Point Partners opened 14 new positions and closed 8 in Q3 2021.
  • Great Point Partners's portfolio value fell 9.9% quarter-over-quarter to $429M.

Based on Great Point Partners's 13F filing for Q3 2021, filed 15 Nov 2021.